Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Lexicon Pharmaceuticals Inc
LXRX | US
1.72
USD-0.04
-2.27%
LXRX | US
About Lexicon Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
10/04/2026
Close
1.72
Open
1.77
High
1.80
Low
1.70
Lexicon Pharmaceuticals Inc. a biopharmaceutical company focuses on the discovery development and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211 which is in Phase II clinical development for the treatment of neuropathic pain and LX2761 which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech Inc. The company was incorporated in 1995 and is headquartered in The Woodlands Texas.
View LessLXRX | US
Risk
61.8
Sharpe
2.75
Luna's Score
54/100
Recommendation
Hold
Luna says (LXRX | US)
What's Working
Positive Momentum
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
69.0%1 month
61.8%3 months
94.4%6 months
82.5%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.03
Debt to equity
0.44
Debt to assets
0.28
Ent. to EBITDA
-2.58
Ent. to rev.
142.11
PEG
-0.14
Other Fundamentals
EBITDA
-196.47M
MarketCap
621.77M
MarketCap(USD)
621.77M
Div. yield
-
Op. margin
-3.36K
Erngs. growth
-63.40
Rev. growth
419.60
Ret. on equity
-94.81
Short ratio
11.39
Short perc.
16.55
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.35
Range1M
0.35
Range3M
0.74
Volumes: Market Activity
Rel. volume
0.55
Price X volume
2.32M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.58 | - | Cheaper |
| Ent. to Revenue | 142.11 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.03 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 94.44 | - | Riskier |
| Debt to Equity | 0.44 | -1.23 | Expensive |
| Debt to Assets | 0.28 | 0.25 | Par |
| Market Cap | 621.77M | - | Emerging |
